Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Aug 9;28(11):1307-1312.
doi: 10.1097/GME.0000000000001844.

The effect of hormone therapy on breast density following risk-reducing salpingo-oophorectomy in women with an increased risk for breast and ovarian cancer

Mark van Barele  1 , Chistien C M Buis  2   3 , Monique M A Brood-van Zanten  4 , H Lena C van Doorn  2 , Katja N Gaarenstroom  5 , Bernadette A M Heemskerk-Gerritsen  1 , Maartje J Hooning  1 , Joanne de Hullu  6 , Marian J Mourits  7 , Curt W Burger  2
Affiliations
Randomized Controlled Trial

The effect of hormone therapy on breast density following risk-reducing salpingo-oophorectomy in women with an increased risk for breast and ovarian cancer

Mark van Barele et al. Menopause. .

Abstract

Objective: To compare the effect of tibolone to conjugated estrogens with medroxyprogesterone-acetate (CEE + MPA) on breast density, as a predictor for breast cancer risk, in women with a high risk of breast and ovarian cancer.

Methods: Women aged 30-50 (N = 114) who had undergone risk-reducing salpingo-oophorectomy (RRSO) were randomized to tibolone or CEE + MPA.

Results: Breast density decreased 46% after RRSO in untreated women, 39% after treatment with tibolone, and 17% after treatment with CEE + MPA; the decrease in breast density after CEE + MPA was significantly different compared with that of untreated women (P = 0.017).

Conclusions: A decline in breast density is seen after premenopausal RRSO despite the use of both CEE + MPA or tibolone, although lower breast density is seen after tibolone use.

PubMed Disclaimer

Conflict of interest statement

Financial disclosure/conflicts of interest: None reported.

References

    1. Muka T, Oliver-Williams C, Kunutsor S, et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis. JAMA Cardiol 2016; 1:767–776.
    1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321–333.
    1. Beral V. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362:419–427.
    1. Gompel A, Chaouat M, Jacob D, Perrot JY, Kloosterboer HJ, Rostene W. In vitro studies of tibolone in breast cells. Fertil Steril 2002; 78:351–359.
    1. Valdivia I, Campodonico I, Tapia A, Capetillo M, Espinoza A, Lavin P. Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. Fertil Steril 2004; 81:617–623.

Publication types

Associated data

LinkOut - more resources